Analyst consensus
As at 12 May 2023
FY23
|
|
Low |
High |
Average (Mean) |
|
Revenue (£m) |
1,267.0 |
1,347.7 |
1,295.0 |
|
EBITDA (£m) |
223.7 |
240.6 |
231.5 |
|
EBIT (£m) |
121.0 |
138.5 |
128.3 |
|
PBT (£m) |
25.5 |
42.7 |
33.4 |
|
Net income (£m) |
16.6 |
27.8 |
21.5 |
|
Adjusted EPS (p) |
4.0 |
6.9 |
5.6 |
|
Net bank debt (£m) |
(251.5) |
(211.0) |
(230.2) |
|
Net debt (including lease liabilities) (£m) |
(1,115.0) |
(1,090.6) |
(1,102.2) |
FY24
|
|
Low |
High |
Average (Mean) |
|
Revenue (£m) |
1,322.2 |
1,428.3 |
1,371.6 |
|
EBITDA (£m) |
249.3 |
265.3 |
258.2 |
|
EBIT (£m) |
135.0 |
158.8 |
149.5 |
|
PBT (£m) |
41.0 |
63.1 |
54.3 |
|
Net income (£m) |
27.8 |
47.3 |
38.4 |
|
Adjusted EPS (p) |
8.0 |
11.8 |
9.9 |
|
Net bank debt (£m) |
(240.3) |
(157.0) |
(198.2) |
|
Net debt (including lease liabilities) (£m) |
(1,098.0) |
(1,061.4) |
(1,074.5) |
The figures shown above are on an adjusted, post IFRS 16 basis. They include estimates from eight analysts at the following institutions who have updated their estimates in line with Company guidance following Spire Healthcare’s FY22 results: Barclays, Berenberg, JPM, Jefferies, Liberum, Numis, Peel Hunt and RBC.
